greatgenes

What a consumer DNA chip can and cannot tell you

Tests such as 23andMe, AncestryDNA, MyHeritage and FamilyTreeDNA read your DNA with a genotyping chip. A chip is good at common variants and weak at rare ones. Knowing the difference tells you which results to take seriously, which need a clinical test, and why an empty section does not mean you are in the clear.

Positions read
between 574,516 and 992,615 chosen positions, depending on the chip version — not your whole genome
Rare variants
often wrong on a chip; a rare disease-causing variant in raw data needs a clinical test before anything is done about it
BRCA1 and BRCA2
not assessed from a chip by greatgenes; a negative chip result does not rule out a hereditary cancer variant
Polygenic scores
a comparison with other people, not a diagnosis and not your personal risk

What a chip reads well

In short: a chip measures a fixed list of positions where people commonly differ. For common variants chip readings of them are mostly confirmed by sequencing (Weedon et al., BMJ 2021).

A genotyping chip does not read your DNA letter by letter. It checks a set list of positions chosen by the chip maker, mostly common single-letter differences (SNPs) useful for ancestry and relative matching. Consumer chips read between 574,516 and 992,615 such positions, depending on the chip version.

That is enough for well-studied common variants: many medicine-related variants, common traits, and the many small effects that polygenic scores add up. greatgenes recognises the chip version from the file and uses only positions that chip actually measured.

Rare variants: the main source of false alarms

In short: the rarer a variant, the more likely a chip reading of it is wrong. Many rare disease-causing variants reported from raw chip data are not confirmed by a clinical test, and for the rarest variants most are not.

greatgenes takes this into account. If the chip reports a pathogenic variant that is rare (below 0.1 % in the population) or has no known frequency, it is not among the main findings in the Summary, its reliability is shown as “low — needs confirmation”, and the report says that a clinical confirmation test is needed before any conclusion; for two copies it also says that this is a likely chip error. Details are in How greatgenes works: finding priority and reliability.

BRCA1, BRCA2 and other cancer genes

In short: hereditary cancer genes can carry any of a very large number of rare variants, and a chip tests only a handful of them, unreliably. A “nothing found” from a chip is not a negative genetic test.

If cancer runs in your family, ask a doctor or a genetic counsellor about clinical testing, whatever a chip shows.

What a chip does not read at all

For medicines this means that a “normal” result from a chip is not a clinical test. For example, the US Food and Drug Administration advises DPYD testing before treatment with capecitabine or fluorouracil (FDA safety labeling update), and a chip reads only some of the DPYD variants that matter. How the report handles medicine genes: How greatgenes works.

No imputation

In short: greatgenes uses only what your chip measured. It does not guess missing positions.

Some services “fill in” unmeasured positions by estimating them from reference panels (imputation). Imputed genotypes are estimates, and they are least accurate for exactly the rare variants that matter most medically. greatgenes does not impute. As a result some modern polygenic scores, built for imputed genomes, are not used, and every genotype in your report is one your chip actually read.

Polygenic scores are comparisons, not diagnoses

In short: a polygenic score places you relative to other people. Most people with a high score never develop the condition, and many people with a low score do.

More on how scores work: What is a polygenic score.

What to do with a worrying result

  1. Read the reliability word next to the finding and whether the report flags it as a possible chip error.
  2. Do not make medical decisions on the basis of raw data. A result is not a diagnosis.
  3. Discuss the finding with a doctor or a clinical geneticist and ask whether a clinical test is needed to confirm it.
  4. Never start, stop or change a medicine on your own; show a medicine-related result to your doctor or pharmacist.

Analyse your file — in your browser, without uploading it.

References

  1. Weedon MN et al. Use of SNP chips to detect rare pathogenic variants: retrospective, population based diagnostic evaluation. BMJ 2021. doi:10.1136/bmj.n214
  2. Tandy-Connor S et al. False-positive results released by direct-to-consumer genetic tests highlight the importance of clinical confirmation testing for appropriate patient care. Genet Med 2018. PMID 29565420
  3. Roberts MC, Allen CG, Andersen BL. The FDA authorization of direct-to-consumer genetic testing for three BRCA1/2 pathogenic variants: a twitter analysis of the public’s response. JAMIA Open 2019. doi:10.1093/jamiaopen/ooz037
  4. ClinVar: ACMG recommendations for reporting of secondary findings (NCBI).
  5. Martin AR et al. Clinical use of current polygenic risk scores may exacerbate health disparities. Nat Genet 2019. doi:10.1038/s41588-019-0379-x